Login to Your Account



New PDUFA Date March 21

Somaxon Surprises with NDA Refiling, Still Seeking Partner

By Jennifer Boggs


Monday, January 25, 2010
In pretty short order, the regulatory status of Somaxon Pharmaceuticals Inc.'s insomnia drug Silenor (doxepin) went from having an uncertain timeline to a PDUFA date only two months away, news that surprised Wall Street and sent the company's shares skyrocketing 81.8 percent Friday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription